Pep Grading
United States
RomaniaRetatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trials.
Retatrutide reduces body weight, apnea-hypopnea index, and knee osteoarthritis pain.
Retatrutide
Retatrutide is a first-in-class investigational triple hormone receptor agonist (GIP, GLP-1, and glucagon) developed by Eli Lilly. In the Phase 2 trial (Jastreboff et al., NEJM 2023, n=338), the 12 mg dose achieved 24.2% mean body weight reduction at 48 weeks, with 100% of participants achieving at least 5% weight loss. Multiple Phase 3 TRIUMPH trials are ongoing, with TRIUMPH-4 (Dec 2025) reporting average loss up to 71.2 lbs with osteoarthritis pain relief. Expected FDA approval is 2027-2028.
Metabolic / Triple AgonistGIP Receptor ActivationGLP-1 Receptor ActivationGlucagon Receptor ActivationWeight ManagementMetabolic Health
- Vendors
- 16 vendors
- Sizes
- 5 mg – 60 mg
- Intake
- Injections
Typical dose
0.5-12 mg weekly
Weekly, escalate every 4 weeks
Route
Subcutaneous weekly
Once weekly injection, same day each week.
Cycle
Continuous therapy
Typical duration
Storage
2-8°C
Follow vendor guidance
Marketplace
Vendor listings
16 offers for Retatrutide
| Vendor | Price | Rating | Shipping | COA | Action |
|---|---|---|---|---|---|
Biologix Labs
| $37.97 $44.99 $7.59/mg −15.6% | No reviews | 2 Days United States, Canada | 1 file | |
Trulab Peptides
| $39.00 $7.80/mg | No reviews | 2–5 days Worldwide | 1 file | |
HLX LABS
| $39.98 $54.99 $4.00/mg −27.3% | No reviews | 2–5 days United States | 1 file | |
Certa Peptides
| $44.49 $8.90/mg | No reviews | 1–4 days Switzerland, United Kingdom +29 | 1 file | |
idunpeptides
| $44.99 $2.25/mg | No reviews | 3–7 days United States, United Kingdom +1 | 3 files | |
Amino Club
| $45.49 $69.99 $4.55/mg −35% | No reviews | 1–4 days United States | 1 file | |
Peptix USA
| $59.03 $67.00 $5.90/mg −11.9% | No reviews | 3–5 days United States | 2 files | |
Giga Compounds
| $60.00 $6.00/mg | No reviews | 2 days United States | 1 file |
What the research reports
Reported research benefits.
Outcomes described across the published literature and ongoing study, not promised results. Read each as research context, not a personal guarantee.
01
Significant weight loss potential
02
Triple receptor activation
03
Metabolic enhancement
04
Appetite control
Dosage and protocol
How it is typically studied.
Retatrutide is a triple agonist (GLP-1/GIP/glucagon) in clinical trials showing up to 24% weight loss. Dosing follows careful titration from 1mg to 12mg weekly. Half-life: ~6 days.
01 Route
Subcutaneous weekly
02 Example range
1mg → 2mg → 4mg → 8mg → 12mg
03 Frequency
Weekly, escalate every 4 weeks
04 Timing
Once weekly injection, same day each week.
Educational reference only. Use clinician guidance for dosing decisions.
Evidence
What the studies actually show.
Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial.
Retatrutide produced dose-dependent weight loss up to 24.2% at 48 weeks versus 2.1% for placebo.
Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA.
Retatrutide improved HbA1c by up to 2.02% and reduced body weight by up to 16.94% in type 2 diabetes.
Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial.
Retatrutide reduced total body fat mass by 15-26% vs placebo in type 2 diabetes.
Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial.
Retatrutide reduced liver fat by up to 82.4% at 24 weeks, with 86% achieving normal liver fat levels.
Interactions
How it pairs with other peptides.
Oral medications
Retatrutide's GLP-1 activity may delay gastric emptying and potentially alter the absorption or timing of some oral medications.
Other GLP-1 receptor agonists
Concurrent use has not been adequately studied and may produce overlapping gastrointestinal and metabolic effects.
Drugs affecting heart rate
Retatrutide has been associated with dose-dependent increases in heart rate in clinical trials, so combinations with other heart-rate–raising agents may warrant caution.
FAQ
Frequently asked questions.
Retatrutide is a triple agonist peptide representing the cutting edge of weight loss research. It targets GLP-1, GIP, and glucagon receptors simultaneously, showing remarkable results in clinical trials for weight reduction.